Scope This Clinical Reference Group (CRG) covers specialised treatment of certain immunological and allergic conditions. In relation to immunological conditions, this includes primary immunodeficiencies, autoimmune and autoinflammatory disease where there is associated immunodeficiency, complex autoimmune and vasculitic conditions and autoinflammatory syndromes. In relation to allergic conditions this includes severe, complex and/or rare sub-groups. Membership Dr. […]

A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate. These are important documents that are developed to ensure consistency in access to treatments nationwide. Abatacept for […]

This policy document outlines the arrangements for funding of treatment for people with congenital haemophilia A with factor VIII inhibitors.

NHS England will commission emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors in accordance with the criteria outlined in this policy.

Contents Commissioning position Evidence and policy summary Implementation Eligibility criteria Exclusion criteria and cautions Pregnancy and women of childbearing potential Dose Co-administration Safety reporting Marketing authorisation Governance Off-label use of medication Data collection requirement Clinical outcome review Policy review date Equality statement Definitions References Rapid Policy Statement Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or […]

Contents Commissioning position Evidence and policy summary Implementation Governance Equality statement Definitions References   Publications approval reference: C1600 Rapid Policy Statement 31 January 2022 Commissioning position The proposal is: Tocilizumab is recommended to be available as a treatment option through routine commissioning for adult patients (aged 18 years and older) hospitalised with COVID- 19 in […]

The purpose of these materials is to signpost stakeholders to key technical documents for financial planning, provide anticipated timescales for publication of materials and links associated for access.

NHS England and the Health and Social Care Information Centre (HSCIC) have announced the start of a new procurement process for an expanded framework of services and solutions for GP practices. The new GP System of Choice (GPSoC) contract will build on the success of the existing contract that has been in place since 2007. […]

This document contains information on the Prescribed Services Commissioning for Quality and Innovation (CQUIN) scheme 2017-19: BI1 Improving Hepatitis C Virus treatment pathways through Operational Delivery Networks.

Child Immunisation Q1 – Q4 2014/15 Today NHS England published the latest experimental management information relating to Child Immunisation data for Q1 – Q4 2014/15. The data includes: DTaP/IPV/Hib – 12 month & 24 month MenC Primary – 12 month, 24 month & 5 year Hib Primary – 5 year PCV primary – 12 month […]